ArticleOrthopaedic journal of sports medicine2025
Return to Previous Levels of Performance Around 10 Months After Anterior Cruciate Ligament Reconstruction Using Bone-Patellar Tendon-Bone Autograft Does Not Delay Signal Intensity Reduction in a Graft: A Serial 3.0-T MRI Study.
Article in Orthopaedic journal of sports medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many athletes expect to return to previous levels of performance (RTP) within 12 months after anterior cruciate ligament (ACL) reconstruction (ACLR) while ACL graft remodeling takes from 6 to 48 months. Therefore, RTP might deteriorate the ACL graft remodeling process. Purpose/Hypothesis: The purpose of this study was to evaluate the changes of signal intensity in ACL graft and assess whether RTP affects ACL graft remodeling after ACLR using bone-patellar tendon-bone (BPTB) autograft with a serial 3.0-T magnetic resonance image (MRI) at 6, 12, and 24 months. It was hypothesized that signal intensity reduction in ACL graft on MRI might be delayed by RTP within 12 months after ACLR using BPTB autograft. Study Design: Cross-sectional study; Level of evidence, 3. Methods: This retrospective cohort study consisted of 115 patients (48 male, 67 female) who underwent primary ACLR using BPTB autograft between 2018 and 2021, including 4 female patients with ACL graft rupture within 24 months. The signal-to-noise quotient (SNQ) values at intra-articular ACL graft on serial MRIs and the amount of change in SNQ value (1) from 6 to 12 months after ACLR (ΔSNQ [6-12]) and (2) from 12 to 24 months after ACLR (ΔSNQ [12-24]) were calculated. Patients were divided into 2 groups depending on whether patients were able to RTP (group A) or not (group B). To investigate the associated factors with ΔSNQ (6-12) and ΔSNQ (12-24), a fixed-effect multivariate logistic regression analysis was conducted with age, sex, body mass index (BMI), cartilage injury, postoperative Tegner score, and RTP as associated variables. Results: Of 111 patients with ≥24 months follow-up, 83 patients (74.8%) were able to RTP within a mean time of 10.4 months (range, 6.5-18 months). The mean ± SD SNQ values (6 months, 1.21 ± 1.94; 12 months, 1.16 ± 2.38; 24 months, 1.42 ± 2.65) did not vary over time. Mean ± SD ΔSNQ (6-12) and ΔSNQ (12-24) were -0.05 ± 2.29 and 0.26 ± 1.83, respectively. There were no significant differences in the SNQ values and ΔSNQs between groups A and B. The multivariate logistic regression analysis showed that postoperative Tegner score and RTP were not associated with ΔSNQ while higher BMI increased ΔSNQ (6-12) (odds ratio, 1.147; 95% CI, 1.016-1.295; Conclusion: RTP around 10 months after ACLR using BPTB autograft was not associated with SNQ reduction in ACL graft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.